FLGT · Fulgent Genetics, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$32.35M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | $17.1M | Q2 2026 | — |
|
|
|||
| Cash, cash equivalents, restricted cash, and investments in marketable securities | $551.5M | second quarter of 2026 | — |
|
|
|||
| Non-GAAP (loss) income attributable to Fulgent non-GAAP | -$16.17M | Three Months Ended June 30, 2026 | — |
| Non-GAAP (loss) income per common share attributable to Fulgent - Basic non-GAAP | -$0.58 | Three Months Ended June 30, 2026 | — |
| Non-GAAP (loss) income per common share attributable to Fulgent - Diluted non-GAAP | -$0.58 | Three Months Ended June 30, 2026 | — |
| Non-GAAP gross margin non-GAAP | 31.8% | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating margin non-GAAP | -26.9% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FLGT
this stock
Fulgent Genetics, Inc.
|
$540.54M | -24.2% | +2.5% | — | 9.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$231.21B | +8.3% | +14.5% | 33.6 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -5.7% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.86B | +41.8% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -19.3% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FLGT | +6.8% | -0.3% | +29.9% | +20.4% | -24.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +8.8% | -3.6% | +18.8% | +18.3% | -36.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.